CSL fell -4.8% to a four-month low following the release of AEGIS-II Phase 3 trials results showing that the plasma-derived treatment did not prevent secondary heart attacks. CSL has spent the greater part of two decades and almost $1 billion to develop the treatment, so yesterday was a setback.
What, CSL spent two decades and $1 billions to develop a treatment. Wow, and certain people on here were winging about MSB taking so long and spending around the same amount! funny people talk a lot of rubbish!
CSL fell -4.8% to a four-month low following the release of...
-
- There are more pages in this discussion • 1,064 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |